- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04907799
Daily Caloric Restriction in ADPKD
Daily Caloric Restriction in Overweight and Obese Adults With ADPKD
Study Overview
Status
Intervention / Treatment
Detailed Description
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by development and continued growth of numerous fluid-filled renal cysts that ultimately result in renal failure. Similar to the general population, the prevalence of overweight and obesity have been rising in ADPKD patients, effecting about two-thirds of individuals. Adipocytes do not simply act as a fat reservoir, but are active endocrine organs that promote release of pro-inflammatory cytokines, and thus, may be a promising clinical target for ADPKD management. Mounting evidence also suggests that a metabolic defect exists in ADPKD, which likely contributes to cystic epithelial proliferation and subsequent cyst growth. Additionally, the investigators recently reported that overweight and obesity are strong independent predictors of more rapid kidney growth. Collectively, these data suggest that interventions to reduce abdominal adiposity may slow ADPKD progression.
Initial results from the investigators' R03-funded pilot and feasibility study support that a 12-month daily caloric restriction (DCR)-based behavioral weight loss intervention in adults with ADPKD and overweight or obesity: 1) is feasible and acceptable; 2) slowed kidney growth (annual %∆ in height-adjusted TKV [htTKV]), which was highly correlated with weight loss; 3) reduced abdominal adiposity; and 4) altered pathways implicated in ADPKD progression and metabolism. These initial results suggest that a DCR-based behavioral weight loss intervention offers a promising strategy to slow ADPKD progression. However, the pilot and feasibility study was limited by a small sample size, relatively short duration, and lack of a control group. Thus, to translate these promising results of the pilot study towards clinical practice, the investigators are conducting a randomized, controlled clinical trial in a larger number of adults with ADPKD and overweight or obesity to directly compare the efficacy of a DCR-based behavioral weight loss intervention compared to control for slowing kidney growth (primary outcome) over a longer duration. Changes in abdominal adiposity will serve as a secondary outcome and effects of weight loss on circulating and adipose markers of biological pathways will provide mechanistic insight.
In a subset of participants recruited for this clinical trial, we will measure change in kidney oxidative metabolism, insulin sensitivity, plasma metabolomics, and gut microbiota. These additional measures will aim to compare kidney oxidative metabolism, insulin sensitivity, plasma metabolome and gut microbiota at baseline and 2 years. In addition, the investigators aim to define the relations among changes in kidney oxidative metabolism, insulin sensitivity, plasma metabolome, gut microbiota, total kidney volume, and body weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure, substrate utilization, plasma metabolomics, or the gut microbiome.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Emily Andrews
- Phone Number: 303-724-7790
- Email: Emily.S.Andrews@cuanschutz.edu
Study Contact Backup
- Name: Kristen Nowak, PhD, MPH
- Phone Number: 303-724-4842
- Email: Kristen.Nowak@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado - Anschutz Medical Campus
-
Contact:
- Kristen Nowak, PhD, MPH
- Phone Number: 303-724-4842
- Email: Kristen.Nowak@cuanschutz.edu
-
Principal Investigator:
- Kristen Nowak, PhD, MPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-65 years of age
- ADPKD diagnosis based on the modified Pei-Ravine criteria
- Body-mass index of 25-45 kg/m^2
- Estimated glomerular filtration rate ≥ 30 mL/min/1.73m^2
- Total kidney volume (htTKV) > 600 mL, calculated from a previous kidney ultrasound or magnetic resonance imaging performed within the last 12 months
- Access to the internet with video chat capabilities
- No plans for extended travel (>2 weeks) without internet access during the 12-month intensive period
- Not currently participating in or planning to participate in any formal weight loss or physical activity program, or another interventional study
- Ability to provide informed consent
Exclusion Criteria:
- Diabetes mellitus
- Current smokers or history of smoking in the past 12 months
- Alcohol dependence or abuse
- History of hospitalization or major surgery within the last 3 months
- Untreated dyslipidemia
- Uncontrolled hypertension
- Pregnancy, lactation, or unwillingness to use adequate birth control
- Cardiovascular disease, peripheral vascular disease, or symptoms suggestive of cardiovascular disease: chest pain, shortness of breath at rest or with mild exertion, syncope
- Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal premature ventricular contractions (PVC's), frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects
- Significant pulmonary disease including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma
- Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism
- History of clinically diagnosed eating disorder including: anorexia nervosa, bulimia, binge eating disorder
- Weight loss of >5% in the past 3 months for any reason except post-partum weight loss; weight gain >5% requires assessment by PI
- Major psychiatric disorder (e.g., psychosis, schizophrenia, mania, bipolar disorder) or current severe depression, based on DSM-IV-TR criteria for Major Depressive Episode, which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions)
- Inability to cooperate with or clinical contraindication for magnetic resonance imaging, including: severe claustrophobia, implants, devices, or non-removable body piercings
- Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed > 1 year before screening, (2) lap banding if the band has been removed > 1 year before screening, (3) intragastric balloon if the balloon has been removed > 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed > 1 year before screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Daily Caloric Restriction
The daily caloric restriction group will participate in a 2-year, group-based, behavioral weight loss intervention based on a 30% reduction in caloric intake and increased physical activity.
|
Weight loss based on daily caloric restriction and increased physical activity
|
Other: Standard Advice Control
The standard advice control group will receive an initial consultation with a registered dietician regarding current clinical recommendations for ADPKD without subsequent counseling sessions.
|
Initial nutrition consultation without subsequent counseling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in height-Adjusted Total kidney volume
Time Frame: Baseline, 24-months
|
To assess kidney growth, we will measure height-adjusted total kidney volume by magnetic resonance imaging at baseline and 24 months to determine annual percent change.
|
Baseline, 24-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in abdominal adiposity
Time Frame: Baseline, 24-months
|
Abdominal adiposity (subcutaneous, visceral, and total) will be assessed by magnetic resonance imaging.
|
Baseline, 24-months
|
Change in the ratio of insulin-like growth factor-1 (IGF-1)/ to GF binding protein-1
Time Frame: Baseline, 12-months, 24-months
|
Venous blood samples will be analyzed for this mechanistic biomarker
|
Baseline, 12-months, 24-months
|
Change in adiponectin (circulating)
Time Frame: Baseline, 12-months, 24-months
|
Venous blood samples will be analyzed for this mechanistic biomarker
|
Baseline, 12-months, 24-months
|
Change in leptin (circulating)
Time Frame: Baseline, 12-months, 24-months
|
Venous blood samples will be analyzed for this mechanistic biomarker
|
Baseline, 12-months, 24-months
|
Change in intereukin-6 (circulating)
Time Frame: Baseline, 12-months, 24-months
|
Venous blood samples will be analyzed for this mechanistic biomarker
|
Baseline, 12-months, 24-months
|
Change in tumor necrosis factor-alpha (circulating)
Time Frame: Baseline, 12-months, 24-months
|
Venous blood samples will be analyzed for this mechanistic biomarker
|
Baseline, 12-months, 24-months
|
Change in C-reactive protein (circulating)
Time Frame: Baseline, 12-months, 24-months
|
Venous blood samples will be analyzed for this mechanistic biomarker
|
Baseline, 12-months, 24-months
|
Change in peripheral blood mononuclear cell protein expression of pAMPK/AMPK
Time Frame: Baseline, 12-months, 24-months
|
PBMCs will be isolated from whole blood to assess protein expression
|
Baseline, 12-months, 24-months
|
Change in peripheral blood mononuclear cell protein expression of pS6K/S6K
Time Frame: Baseline, 12-months, 24-months
|
PBMCs will be isolated from whole blood to assess protein expression
|
Baseline, 12-months, 24-months
|
Change in adiponectin (adipose tissue)
Time Frame: Baseline, 24-months
|
A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker.
|
Baseline, 24-months
|
Change in leptin (adipose tissue)
Time Frame: Baseline, 24-months
|
A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker.
|
Baseline, 24-months
|
Change in interleukin-6 (adipose tissue)
Time Frame: Baseline, 24-months
|
A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker.
|
Baseline, 24-months
|
Change in tumor necrosis factor-alpha (adipose tissue)
Time Frame: Baseline, 24-months
|
A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker.
|
Baseline, 24-months
|
Change in renal oxygen consumption
Time Frame: Baseline, 24-months
|
Renal oxygen consumption will be assessed by a PET/CT scan using 11-C acetate in a sub-set of participants
|
Baseline, 24-months
|
Change in gut microbiota
Time Frame: Baseline, 24-months
|
16S rRNA gene sequencing will be used for taxonomic characterization of the gut microbiota in a subset of participants.
|
Baseline, 24-months
|
Change in plasma metabolome
Time Frame: Baseline, 24-months
|
Untargeted plasma metabolomics will be performed using high-performance liquid chromatography-tandem mass spectrometry in a subset of participants.
|
Baseline, 24-months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (adverse events)
Time Frame: 24-months
|
Number of participants with treatment-related adverse events in each group as evaluated by the DSMB
|
24-months
|
Change in dietary Energy Intake
Time Frame: Baseline, 1-, 6-, 12-, and 24-months
|
Multiple pass 24-hr dietary recalls will be analyzed to evaluate self-reported energy intake
|
Baseline, 1-, 6-, 12-, and 24-months
|
Adherence
Time Frame: 24 months
|
Self-reported dietary adherence using a 1-10 likert scale (10 is highest adherence)
|
24 months
|
Tolerability (dropout due to adverse events)
Time Frame: 24 months
|
Subject dropout due to treatment-emergent adverse events
|
24 months
|
Change in free-living physical activity
Time Frame: Baseline, 6-, 12- and 24-months
|
Estimated energy expenditure (METs) over a 7-day period will be quantified using the activPAL3 micro.
|
Baseline, 6-, 12- and 24-months
|
Change in percent body fat
Time Frame: Baseline, 24-months
|
Percent body fat will be assessed via DEXA scan in a sub-set of participants.
|
Baseline, 24-months
|
Change in plasma choline
Time Frame: Baseline, 24-months
|
Plasma choline will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants.
|
Baseline, 24-months
|
Change in plasma trimethylamine
Time Frame: Baseline, 24-months
|
Plasma trimethylamine will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants.
|
Baseline, 24-months
|
Change in plasma trimethylamine-N-oxide
Time Frame: Baseline, 24-months
|
Plasma trimethylamine-N-oxide will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants.
|
Baseline, 24-months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kristen Nowak, PhD, MPH, University of Colorado - Anschutz Medical Campus
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Congenital Abnormalities
- Overnutrition
- Nutrition Disorders
- Body Weight
- Genetic Diseases, Inborn
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Ciliopathies
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Overweight
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
Other Study ID Numbers
- 21-2999
- R01DK129259 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
-
University of British ColumbiaTerminatedOverweight and ObesityCanada
-
National Taiwan University HospitalCompleted
Clinical Trials on Daily caloric restriction
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
PfizerUniversity of Adelaide; Royal Adelaide HospitalCompleted
-
Federal University of Minas GeraisRecruiting
-
University of FloridaTerminatedObesity | Diabetes Mellitus, Type 2 | NAFLDUnited States
-
Karolinska University HospitalCompleted
-
Centre d'Alt RendimentCompleted
-
Korea UniversityEulji University HospitalCompletedOverweight | Type 2 DiabetesKorea, Republic of
-
University Hospital, MontpellierUnknownType 2 Diabetes | Severe ObesityFrance
-
Federico II UniversityFondazione Italiana Sclerosi MultiplaRecruitingMultiple Sclerosis, Relapsing-Remitting | Caloric RestrictionItaly
-
Wake Forest University Health SciencesActive, not recruiting